Seneffe, Belgium, November 13th, 2014. Eckert & Ziegler BEBIG is proud to announce that it has provided more than 250 MultiSource® afterloading devices worldwide. Holding the CE mark for MultiSource® for 10 years now, the unique HDR afterloader has been delivered in more than 40 countries and is an integral device to fight cancer in many clinical institutions.
As a complete brachytherapy provider, Eckert & Ziegler BEBIG can look back on a long record of experience in HDR brachytherapy. The first afterloader developed by an Eckert & Ziegler BEBIG predecessor company was a one-channel device using iridium-192 in 1973. The development of a first afterloader with 20-channel support capable of using an iridium-192 or a miniaturized cobalt-60 source started in 1998 and resulted in the global market launch of MultiSource® in October 2004. The successful introduction of the miniaturized cobalt-60 source made it possible for physicians to take advantage of the isotope's long half-life and perform even small-diameter applications.
The success of MultiSource®, with more than 250 deliveries worldwide, is the result of the afterloader's unique features. It is the only device to offer integrated in-vivo dosimetry for real-time dose verification and enhances patient safety thanks to automatic catheter-length measurement and a precise source-position check using a digital camera.
What's more, MultiSource® is still the only certified afterloader in clinical use with a long-lasting cobalt-60 source that can also be equipped with iridium-192. "Thanks to the long half-life of cobalt-60, the source can be used for up to five years. Approximately 20 source exchanges of iridium-192 would have to be performed during the recommended working life of a single cobalt-60 source. The amount of time saved on quality assurance for exchange processes makes the use of cobalt-60 particularly attractive for high-volume clinics. Clinics in countries with demanding logistics also benefit greatly from the use of cobalt-60, since it allows them to invest less time and money in dealing with customs formalities," Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG, says.
These unequaled advantages have led to more than 220 cobalt-60 MultiSource® afterloaders being delivered all over the world since the receipt of the CE mark 10 years ago.
About Eckert & Ziegler BEBIG
Contributing to saving lives
Eckert & Ziegler BEBIG is a European group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy.
The company's headquarters are located in Belgium, with production facilities in Germany and in the U.S., as well as subsidiaries throughout Europe, the U.S., Russia, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line.
The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 200 people. The company has been listed on the Euronext stock exchange since April 1997.
Head of Marketing
Tel.: +49 30 9410 84 272